CXCR4 expression is associated with proneural‐to‐mesenchymal transition in glioblastoma
Authors:
- A. Basit KhanAKA. Basit Khan
- Sungho LeeSLSungho Lee
- Akdes Serin HarmanciAHAkdes Serin Harmanci
- Rajan PatelRPRajan Patel
- Khatri LathaKLKhatri Latha
- Yuhui YangYYYuhui Yang
- Hyun‐Kyoung LeeHLHyun‐Kyoung Lee
- Amy B. HeimbergerAHAmy B. Heimberger
- Gregory N. FullerGFGregory N. Fuller
- Benjamin DeneenBDBenjamin Deneen
- Ganesh RaoGRGanesh Rao
Open Access
- 31 October 2022
- journal article
- research article
- Published by Wiley in International Journal of Cancer
- Vol. 152 (4) , 713-724
Abstract
Glioblastoma (GBM) is the most common primary intracranial malignant tumor and consists of three molecular subtypes: proneural (PN), mesenchymal (MES) and classical (CL). Transition between PN to MES subtypes (PMT) is the glioma analog of the epithelial‐mesenchymal transition (EMT) in carcinomas and is associated with resistance to therapy. CXCR4 signaling increases the expression of MES genes in glioma cell lines and promotes EMT in other cancers. RNA sequencing (RNAseq) data of PN GBMs in The Cancer Genome Atlas (TCGA) and secondary high‐grade gliomas (HGGs) from an internal cohort were examined for correlation between CXCR4 expression and survival as well as expression of MES markers. Publicly available single‐cell RNA sequencing (scRNAseq) data was analyzed for cell type specific CXCR4 expression. These results were validated in a genetic mouse model of PN GBM. Higher CXCR4 expression was associated with significantly reduced survival and increased expression of MES markers in TCGA and internal cohorts. CXCR4 was expressed in immune and tumor cells based on scRNAseq analysis. Higher CXCR4 expression within tumor cells on scRNAseq was associated with increased MES phenotype, suggesting a cell‐autonomous effect. In a genetically engineered mouse model, tumors induced with CXCR4 exhibited a mesenchymal phenotype and shortened survival. These results suggest that CXCR4 signaling promotes PMT and shortens survival in GBM and highlights its inhibition as a potential therapeutic strategy.Keywords
Funding Information
- National Cancer Institute (CA223388)
- National Institute of Neurological Disorders and Stroke (R01 NS094615)
- National Institutes of Health (R01 CA120813)
This publication has 49 references indexed in Scilit:
- Intratumor heterogeneity in human glioblastoma reflects cancer evolutionary dynamicsProceedings of the National Academy of Sciences, 2013
- Mechanisms of chemoresistance in cancer stem cellsClinical and Translational Medicine, 2013
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics DataCancer Discovery, 2012
- The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant gliomaGenes & Development, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- The basics of epithelial-mesenchymal transitionJournal of Clinical Investigation, 2009
- Comprehensive genomic characterization defines human glioblastoma genes and core pathwaysNature, 2008
- BevacizumabDrugs, 2008
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005
- What does Stat3 do?Journal of Clinical Investigation, 2002